- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Aprocitentan Now Available in the US for Treatment-Resistant Hypertension
Aprocitentan is the first-and-only dual endothelin receptor antagonist approved for the treatment of systemic hypertension.
Aprocitentan (Tryvio) is now available to prescribe in the US for the treatment of hypertension (HTN), in combination with other antihypertensive medications, in adults whose blood pressure (BP) is not adequately controlled by other medications.
In March, once-daily aprocitentan became the first FDA-approved treatment for systemic HTN targeting the endothelin system, a key pathway in the pathophysiology of HTN, according to a news release from manufacturer Idorsia.
The decision was based on the phase 3 PRECISION clinical trial which showed that the joint endothelin A/endothelin B receptor agonist reduced systolic BP by 15.4 mm Hg from baseline at 4 weeks (primary endpoint) when added to standardized background therapy of at least 3 antihypertensive medications, including a diuretic. Aprocitentan was well-tolerated and the most frequently reported adverse events were edema/fluid retention and anemia.
"Uncontrolled hypertension can increase the risk of life-threatening conditions, such as major adverse cardiovascular and cerebrovascular events. For patients with comorbid conditions such as diabetes, chronic kidney disease, and heart failure, these issues pose an increased burden,” Michael Weber, MD, professor of medicine, division of cardiovascular medicine, State University of New York, said in a press release. “TRYVIO provides physicians with a therapeutic option targeting a previously unaddressed pathway to address the millions of patients with hypertension whose blood pressure is not adequately controlled despite being treated with the existing standards of care."
Reference: Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension. News release. Idorsia Pharmaceuticals US Inc. November 15, 2024. Accessed November 15, 2024. https://www.prnewswire.com/news-releases/idorsias-once-daily-tryvio-aprocitentan-is-now-available-in-the-us-advancing-treatment-options-for-millions-of-patients-with-difficult-to-control-hypertension-302306837.html
